was read the article
array:24 [ "pii" => "S2173505012000210" "issn" => "21735050" "doi" => "10.1016/j.rpsmen.2012.04.007" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "aid" => "145" "copyright" => "SEP y SEPB" "copyrightAnyo" => "2011" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Rev Psiquiatr Salud Ment. 2012;5:37-42" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2524 "formatos" => array:3 [ "EPUB" => 13 "HTML" => 1983 "PDF" => 528 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S1888989111001807" "issn" => "18889891" "doi" => "10.1016/j.rpsm.2011.11.003" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "aid" => "145" "copyright" => "SEP y SEPB" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Rev Psiquiatr Salud Ment. 2012;5:37-42" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 13118 "formatos" => array:3 [ "EPUB" => 18 "HTML" => 11934 "PDF" => 1166 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Clozapina y agranulocitosis en España: ¿tenemos una población más segura? Seguimiento hematológico a 5 años de una cohorte de pacientes tratados con clozapina" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "37" "paginaFinal" => "42" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Clozapine and agranulocitosis in Spain: Do we have a safer population? A 5-year hematologic follow-up" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1378 "Ancho" => 2087 "Tamanyo" => 126516 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Recuento de diferencial leucocitario durante las primeras 18 semanas (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>231).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alexander Pons, Juan Undurraga, Albert Batalla, Miquel Bernardo" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Alexander" "apellidos" => "Pons" ] 1 => array:2 [ "nombre" => "Juan" "apellidos" => "Undurraga" ] 2 => array:2 [ "nombre" => "Albert" "apellidos" => "Batalla" ] 3 => array:2 [ "nombre" => "Miquel" "apellidos" => "Bernardo" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173505012000210" "doi" => "10.1016/j.rpsmen.2012.04.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173505012000210?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1888989111001807?idApp=UINPBA00004N" "url" => "/18889891/0000000500000001/v1_201305031500/S1888989111001807/v1_201305031500/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173505012000209" "issn" => "21735050" "doi" => "10.1016/j.rpsmen.2012.04.006" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "aid" => "144" "copyright" => "SEP y SEPB" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Rev Psiquiatr Salud Ment. 2012;5:43-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2377 "formatos" => array:3 [ "EPUB" => 18 "HTML" => 1780 "PDF" => 579 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Relationship between insight, violence and diagnoses in psychotic patients" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "43" "paginaFinal" => "47" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Relación entre <span class="elsevierStyleItalic">insight</span>, violencia y diagnosis en pacientes con psicosis" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Guillem Lera Calatayud, Neus Herrero Sebastián, Eduardo Aguilar García-Iturrospe, José Carlos González Piqueras, Julio Sanjuán Arias, Carmen Leal Cercós" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Guillem" "apellidos" => "Lera Calatayud" ] 1 => array:2 [ "nombre" => "Neus" "apellidos" => "Herrero Sebastián" ] 2 => array:2 [ "nombre" => "Eduardo" "apellidos" => "Aguilar García-Iturrospe" ] 3 => array:2 [ "nombre" => "José Carlos" "apellidos" => "González Piqueras" ] 4 => array:2 [ "nombre" => "Julio" "apellidos" => "Sanjuán Arias" ] 5 => array:2 [ "nombre" => "Carmen" "apellidos" => "Leal Cercós" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1888989111001790" "doi" => "10.1016/j.rpsm.2011.10.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1888989111001790?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173505012000209?idApp=UINPBA00004N" "url" => "/21735050/0000000500000001/v1_201305031529/S2173505012000209/v1_201305031529/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2173505012000192" "issn" => "21735050" "doi" => "10.1016/j.rpsmen.2012.04.005" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "aid" => "139" "copyright" => "SEP y SEPB" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Rev Psiquiatr Salud Ment. 2012;5:24-36" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2185 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 1666 "PDF" => 511 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Brief Suicide Questionnaire. Inter-rater reliability" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "24" "paginaFinal" => "36" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Protocolo breve de evaluación del suicidio: fiabilidad interexaminadores" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Rebeca García-Nieto, Isabel Parra Uribe, Diego Palao, Jorge Lopez-Castroman, Pilar Alejandra Sáiz, María Paz García-Portilla, Jerónimo Saiz Ruiz, Angela Ibañez, Thais Tiana, Santiago Durán Sindreu, Victor Perez Sola, Yolanda de Diego-Otero, Lucia Pérez-Costillas, Rafael Fernández García-Andrade, Dolores Saiz-González, Miguel Angel Jiménez Arriero, Mercedes Navío Acosta, Lucas Giner, Julio Antonio Guija, José Luis Escobar, Jorge Antonio Cervilla, Marta Quesada, Dolores Braquehais, Hilario Blasco-Fontecilla, Teresa Legido-Gil, Fuensanta Aroca, Enrique Baca-García" "autores" => array:28 [ 0 => array:2 [ "nombre" => "Rebeca" "apellidos" => "García-Nieto" ] 1 => array:2 [ "nombre" => "Isabel Parra" "apellidos" => "Uribe" ] 2 => array:2 [ "nombre" => "Diego" "apellidos" => "Palao" ] 3 => array:2 [ "nombre" => "Jorge" "apellidos" => "Lopez-Castroman" ] 4 => array:2 [ "nombre" => "Pilar Alejandra" "apellidos" => "Sáiz" ] 5 => array:2 [ "nombre" => "María Paz" "apellidos" => "García-Portilla" ] 6 => array:2 [ "nombre" => "Jerónimo Saiz" "apellidos" => "Ruiz" ] 7 => array:2 [ "nombre" => "Angela" "apellidos" => "Ibañez" ] 8 => array:2 [ "nombre" => "Thais" "apellidos" => "Tiana" ] 9 => array:2 [ "nombre" => "Santiago Durán" "apellidos" => "Sindreu" ] 10 => array:2 [ "nombre" => "Victor Perez" "apellidos" => "Sola" ] 11 => array:2 [ "nombre" => "Yolanda" "apellidos" => "de Diego-Otero" ] 12 => array:2 [ "nombre" => "Lucia" "apellidos" => "Pérez-Costillas" ] 13 => array:2 [ "nombre" => "Rafael Fernández" "apellidos" => "García-Andrade" ] 14 => array:2 [ "nombre" => "Dolores" "apellidos" => "Saiz-González" ] 15 => array:2 [ "nombre" => "Miguel Angel Jiménez" "apellidos" => "Arriero" ] 16 => array:2 [ "nombre" => "Mercedes Navío" "apellidos" => "Acosta" ] 17 => array:2 [ "nombre" => "Lucas" "apellidos" => "Giner" ] 18 => array:2 [ "nombre" => "Julio Antonio" "apellidos" => "Guija" ] 19 => array:2 [ "nombre" => "José Luis" "apellidos" => "Escobar" ] 20 => array:2 [ "nombre" => "Jorge Antonio" "apellidos" => "Cervilla" ] 21 => array:2 [ "nombre" => "Marta" "apellidos" => "Quesada" ] 22 => array:2 [ "nombre" => "Dolores" "apellidos" => "Braquehais" ] 23 => array:2 [ "nombre" => "Hilario" "apellidos" => "Blasco-Fontecilla" ] 24 => array:2 [ "nombre" => "Teresa" "apellidos" => "Legido-Gil" ] 25 => array:2 [ "nombre" => "Fuensanta" "apellidos" => "Aroca" ] 26 => array:2 [ "nombre" => "Enrique" "apellidos" => "Baca-García" ] 27 => array:1 [ "colaborador" => "GEICS" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1888989111001479" "doi" => "10.1016/j.rpsm.2011.10.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1888989111001479?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173505012000192?idApp=UINPBA00004N" "url" => "/21735050/0000000500000001/v1_201305031529/S2173505012000192/v1_201305031529/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Clozapine and agranulocytosis in Spain: Do we have a safer population? A 5-year haematologic follow-up" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "37" "paginaFinal" => "42" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Alexander Pons, Juan Undurraga, Albert Batalla, Miquel Bernardo" "autores" => array:4 [ 0 => array:3 [ "nombre" => "Alexander" "apellidos" => "Pons" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:4 [ "nombre" => "Juan" "apellidos" => "Undurraga" "email" => array:2 [ 0 => "jundurra@clinic.ub.es" 1 => "juanundu@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 2 => array:3 [ "nombre" => "Albert" "apellidos" => "Batalla" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "Miquel" "apellidos" => "Bernardo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Programa Esquizofrènia Clínic, Hospital Clínic de Barcelona, Departamento de Psiquiatría y Psicobiología Clínica, Universitat de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain" "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Programa de Trastorno Bipolar, Hospital Clínic de Barcelona, Departamento de Psiquiatría y Psicobiología Clínica, Universitat de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain" "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Programa Esquizofrènia Clínic, Hospital Clínic de Barcelona, Departamento de Psiquiatría y Psicobiología Clínica, Universitat de Barcelona, Barcelona, Spain" "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Programa Esquizofrènia Clínic, Hospital Clínic de Barcelona, Departamento de Psiquiatría y Psicobiología Clínica, Universitat de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain" "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Clozapina y agranulocitosis en España: ¿tenemos una población más segura? Seguimiento hematológico a 5 años de una cohorte de pacientes tratados con clozapina" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1378 "Ancho" => 2087 "Tamanyo" => 129764 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">White blood cell count during first 18 weeks (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>231).</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Clozapine, a second generation antipsychotic, is the treatment of choice for patients with refractory schizophrenia, as it has proved to be more effective than other existing antipsychotics, both typical and atypical.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–7</span></a> Discovered in 1958, it was the first atypical antipsychotic, effective in the treatment of positive and negative schizophrenic symptoms,<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8,9</span></a> which in addition to its favourable profile regarding extrapyramidal adverse effects, generated grand expectations in the scientific and clinical world at that time. However, its development and commercialisation were interrupted in 1975, due to information concerning patients who developed agranulocytosis in Finland while being treated with clozapine.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8,10,11</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">In later years, studies involving blood monitoring were carried out that showed clinically favourable results.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,12</span></a> The use of clozapine was approved by the Food and Drug Administration (FDA) in 1990 as an exclusive treatment for patients with resistant schizophrenia, who would also be subject to strict blood monitoring. Since then, clozapine was progressively reintroduced in 1993 under strict conditions put forth by the Ministry of Health, who insured its controlled use by limiting its applications and enforcing a strict check of differential white blood cell counts before starting treatment, on a weekly basis for the first 18 weeks and on a monthly basis after that (<a class="elsevierStyleCrossRefs" href="#fig0005">Figs. 1 and 2</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">The incidence of agranulocytosis and neutropenia show marked variations, depending on the sample size and the location in which the study was completed.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> In the follow-up cohorts with a larger sample size, an incidence of approximately 1% and 3% was observed for agranulocytosis and neutropenia respectively.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14–16</span></a> Of the agranulocytosis cases, 95% appeared within the first 6 months of treatment, with the risk being even greater in the first 3 months.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> The exact mechanism by which clozapine induces agranulocytosis is not completely clear. There is evidence that it involves an immune-mediated reaction<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> and that certain factors like ethnicity and age of the populations studied could intervene.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14–16,18–21</span></a> We realised how important this drug is for treating resistant patients and how little data regarding the risk of agranulocytosis there is in our population. Consequently, in an effort to evaluate the risk of developing blood dyscrasias, we prepared this prospective 5-year follow-up of a cohort of patients undergoing treatment in the Clozapine Clinic (<a class="elsevierStyleCrossRefs" href="#tbl0005">Tables 1 and 2</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Methods and materials</span><p id="par0020" class="elsevierStylePara elsevierViewall">The study involves a cohort of patients treated in the Clozapine Clinic of Outpatient Care at the Neuroscience Institute in the Hospital Clínico in Barcelona. Patients fulfilled the criteria defined by the ICD-10 for diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder with psychotic symptoms. They began treatment with clozapine due to their resistance to previous antipsychotic treatment. This resistance is defined by the persistence of psychotic symptoms despite consecutive treatment with therapeutic dosages of 2 antipsychotics, administered within 6 months of each other; or also by intolerance to treatment with other antipsychotics due to serious adverse or untreatable neurological reactions (extrapyramidal symptoms or tardive dyskinesia).</p><p id="par0025" class="elsevierStylePara elsevierViewall">For these patients, a white blood cell count and absolute neutrophil count were performed, according to current regulations, weekly during the first 18 weeks of treatment and monthly subsequently.</p><p id="par0030" class="elsevierStylePara elsevierViewall">The plasma concentrations of clozapine and norclozapine were determined by high performance liquid chromatography in a subgroup of 112 patients. We included all of the patients who joined the study after the technique was available in our laboratory in this subgroup.</p><p id="par0035" class="elsevierStylePara elsevierViewall">With reference to the blood evaluations, we considered as criteria for inclusion that the cases had had at least 4 months of follow-up in our centre, and no less than 24 months follow-up for those cases from another centre. The patients who began clozapine treatment before the regulations that dictate follow-up procedure went into effect were also included.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">For the purpose of this study, the definitions used for leucopenia, neutropenia and agranulocytosis are the internationally accepted ones. Leucopenia was defined by a white blood cell count of less than 3<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/L and neutropenia was a neutrophil count between 0.5<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/L and 1.5<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/L. Agranulocytosis was defined as a granulocyte count of less than 0.5<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/L. Likewise, the definitions of neutrophilia and leucocytosis were a neutrophil count of less than 7.5<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/L and a white blood cell count less than 11.5<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">9</span>/L respectively. In this study, the time criterion was defined as 3 consecutive abnormal counts during the weekly follow-up and 2 during the monthly follow-up.</p><p id="par0045" class="elsevierStylePara elsevierViewall">For the analysis of the differences in neutrophil and white blood cell values in the determinations performed, from the initial measure to the following measures, variance analysis was used for repeated measures. To determine the points where significant differences occurred, contrasts that were <span class="elsevierStyleItalic">a priori</span> within subjects were calculated, comparing each determination with the initial one.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Results</span><p id="par0050" class="elsevierStylePara elsevierViewall">The sample consisted of 271 patients, 63.5% of whom were male. The mean age was 32.3 years (standard deviation [SD] 10.5), with an interval that went from 18.2 to 78.7 years. The dosages administered of clozapine during the follow-up were between 25 and 600<span class="elsevierStyleHsp" style=""></span>mg/day. The mean dose administered was 227.6<span class="elsevierStyleHsp" style=""></span>mg/day (SD 118.7), and the median was 200<span class="elsevierStyleHsp" style=""></span>mg/day.</p><p id="par0055" class="elsevierStylePara elsevierViewall">The plasma concentrations of clozapine and norclozapine were monitored in a subgroup of 112 patients from the cohort, composed of 38 females with a mean dose of 207.6<span class="elsevierStyleHsp" style=""></span>mg/day and 74 males with a mean dose of 256<span class="elsevierStyleHsp" style=""></span>mg/day. The plasma concentrations of clozapine and norclozapine were 239.1<span class="elsevierStyleHsp" style=""></span>ng/ml and 138.2<span class="elsevierStyleHsp" style=""></span>ng/ml respectively for women, and 274.7<span class="elsevierStyleHsp" style=""></span>ng/ml and 166.3<span class="elsevierStyleHsp" style=""></span>ng/ml respectively for men.</p><p id="par0060" class="elsevierStylePara elsevierViewall">Of the total 231 cases that completed the first 18 weeks of follow-up, 3 cases of leucopenia (1.3%), 7 cases of neutropenia (3.0%) and no cases of agranulocytosis were observed.</p><p id="par0065" class="elsevierStylePara elsevierViewall">The sharp increase in the neutrophil and white blood cell numbers during the first few weeks attracted attention. This increase reached its maximum point between the second and third week, with there being a significant difference between these counts and the base count. After this point, the count began to decrease progressively until the difference became significant during the last 4 weeks for the neutrophils and during the last 10 weeks for the white blood cells.</p><p id="par0070" class="elsevierStylePara elsevierViewall">During the next 2 years of follow-up, this difference maintained significance (<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.005 according to Pillai's Trace), although the counts tended to stabilise. One new case of leucopenia and neutropenia was observed of the total sample (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>120).</p><p id="par0075" class="elsevierStylePara elsevierViewall">We had a complete monthly follow-up of haematological counts during 5 years for 69 patients. During these years, no new cases of leucopenia or neutropenia were observed and the curve of the count tended to level out towards the limits.</p><p id="par0080" class="elsevierStylePara elsevierViewall">Of the 2 cases mentioned, we decided to suspend treatment in 1 of them in an effort to keep neutrophil numbers low and, in the other, due to the emergence of simple epileptic seizures.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Discussion</span><p id="par0085" class="elsevierStylePara elsevierViewall">In the cohort of patients treated with clozapine, a neutropenia prevalence of 3% was observed, concentrated in the first few months of follow-up, which agrees with data published by other authors.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> No patient presented agranulocytosis.</p><p id="par0090" class="elsevierStylePara elsevierViewall">The majority of patients in the sample had a diagnosis of resistant psychosis or had presented significant adverse effects associated with the use of other antipsychotic treatments.</p><p id="par0095" class="elsevierStylePara elsevierViewall">Estimations on resistant schizophrenia prevalence vary depending on its definition, but it is estimated that between one-fifth and one-third of patients with schizophrenia have a sub-optimal response to antipsychotic treatment. This warrants attention in that, despite current scientific evidence for the benefits of clozapine over other antipsychotics in schizophrenia treatment, this drug continues to be underused.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> In the United States, the percentage of clozapine prescriptions compared to other antipsychotics did not reach 3.5% during the 2008–2009 period.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> In an Italian sample, the percentage observed was 1.5%.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">The prescription of clozapine seems to be limited by its adverse effects like drooling, dizziness, constipation and other symptoms that could potentially increase the morbidity and mortality rate among patients, such as metabolic syndrome, agranulocytosis, myocarditis, cardiomyopathy and a decrease in the seizure threshold. Furthermore, in a recently published study by Tiihonen et al.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a> (in which a 10-year follow-up was carried out for a Finnish cohort of 66,881 patients with a schizophrenia diagnosis), the authors concluded that the patients treated by clozapine had the lowest risk of premature death, compared with the patients who took other antipsychotics and the patients who took no antipsychotics regularly. This protective effect could be partially mediated by the reduction in suicide risk.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> The authors suggested that the restrictions on the use of clozapine “may have caused thousands of premature deaths.”</p><p id="par0105" class="elsevierStylePara elsevierViewall">The fact that the majority of patients under clozapine treatment are resistant or have previously had significant adverse effects to other antipsychotics makes the decision to suspend clozapine treatment difficult. Many physicians consider reinitiating clozapine in patients with a history of neutropenia despite the risk that it might involve.<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">29,30</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">Clozapine can be related to neutropenia both directly (as we previously examined) and indirectly. Examples of the latter include benign ethnic neutropenia, side effects of other drugs administered concomitantly or through interaction with clozapine and medical comorbidity.<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">29</span></a> Methods described for the management of neutropenia in these patients include co-administering lithium, administering granulopoiesis stimulating factors and managing concomitant drugs rationally. While these treatments do provide a safety margin, they have been used in only a limited number of cases and the level of evidence is still weak.<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">29,31,32</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">The protocols associated with clozapine use are extremely costly for the patient and for healthcare services. Current evidence available on the effectiveness and safety of this drug and the results of this study make it appropriate to start reviewing and discussing the protocols for clozapine usage and follow-up. Taking into consideration the greater risk concentrated in the first 6 months of treatment, and the risk of agranulocytosis after the first year–which is equal to that of other drugs not specifying monitoring–we would be in favour of maintaining a weekly follow-up in the first 18 weeks, a monthly follow-up throughout the rest of the first year and a bi-monthly follow-up after that. This change could involve a lower cost for the patient and for healthcare services and could also improve adherence to follow-ups and treatment.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Ethical responsibilities</span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Protection of human and animal subjects</span><p id="par0120" class="elsevierStylePara elsevierViewall">The authors declare that the procedures followed were in accordance with the regulations of the responsible Clinical Research Ethics Committee and in accordance with those of the World Medical Association and the Helsinki Declaration.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Confidentiality of data</span><p id="par0125" class="elsevierStylePara elsevierViewall">The authors declare that they have followed the protocols of their work centre on the publication of patient data and that all the patients included in the study have received sufficient information and have given their informed consent in writing to participate in that study.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Right to privacy and informed consent</span><p id="par0130" class="elsevierStylePara elsevierViewall">The authors must have obtained the informed consent of the patients and/or subjects mentioned in the article. The author for correspondence must be in possession of this document.</p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conflict of interest</span><p id="par0135" class="elsevierStylePara elsevierViewall">Dr. Bernardo has received funds for research and/or has acted as a consultant and/or speaker in activities organised by the following companies: Adamet, Almirall, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Mylan, Pfizer, Rocher and Rovi.</p><p id="par0140" class="elsevierStylePara elsevierViewall">Dr. Pons has acted as a consultant and/or speaker for the following companies: Janssen-Cilag and Johnson & Johnson.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:2 [ "identificador" => "xres115248" "titulo" => array:5 [ 0 => "Abstract" 1 => "Introduction" 2 => "Materials and method" 3 => "Results" 4 => "Conclusions" ] ] 1 => array:2 [ "identificador" => "xpalclavsec102545" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres115249" "titulo" => array:5 [ 0 => "Resumen" 1 => "Introducción" 2 => "Material y métodos" 3 => "Resultados" 4 => "Conclusión" ] ] 3 => array:2 [ "identificador" => "xpalclavsec102546" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Methods and materials" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Results" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Discussion" ] 8 => array:3 [ "identificador" => "sec0025" "titulo" => "Ethical responsibilities" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0030" "titulo" => "Protection of human and animal subjects" ] 1 => array:2 [ "identificador" => "sec0035" "titulo" => "Confidentiality of data" ] 2 => array:2 [ "identificador" => "sec0040" "titulo" => "Right to privacy and informed consent" ] ] ] 9 => array:2 [ "identificador" => "sec0045" "titulo" => "Conflict of interest" ] 10 => array:2 [ "identificador" => "xack37114" "titulo" => "Acknowledgements" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2011-08-22" "fechaAceptado" => "2011-11-28" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec102545" "palabras" => array:3 [ 0 => "Agranulocytosis" 1 => "Neutropenia" 2 => "Clozapine" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec102546" "palabras" => array:3 [ 0 => "Agranulocitosis" 1 => "Neutropenia" 2 => "Clozapina" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span class="elsevierStyleSectionTitle">Introduction</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clozapine is an effective antipsychotic. However, its use has been associated with agranulocytosis. For this reason, it has been restricted for the treatment of resistant schizophrenia under a strict haematologic control. The objective of this work was to assess the risk of haematologic dyscrasias in a sample of clozapine-treated patients in a 5-year period.</p> <span class="elsevierStyleSectionTitle">Materials and method</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">This is a follow-up study in a cohort of clozapine-treated patients in which the risk of haematological dyscrasias was assessed. Complete blood cell count was made for each patient in a weekly basis for the first 18 weeks and thereafter monthly.</p> <span class="elsevierStyleSectionTitle">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">271 patients in treatment with clozapine were followed up. The mean age was 32.3 years, with 36.5% women. The mean dose was 2276<span class="elsevierStyleHsp" style=""></span>mg, ranging from 25 to 600<span class="elsevierStyleHsp" style=""></span>mg/day. During the first 18 weeks of follow-up, we observed a 3% incidence of neutropenia and 1.3% of leucopenia. During the next 2 years, only 1 new case of neutropenia and leucopenia was observed (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>120). No new cases were observed during the rest of follow up (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>69). No cases of agranulocytosis were observed.</p> <span class="elsevierStyleSectionTitle">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">A 3% incidence of neutropenia concentrated in the first months of follow up and no cases of agranulocytosis were observed in our sample. Actual evidence on clozapine effectiveness and safety and the results of this study suggests that a critical revision of follow-up protocols is suitable.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span class="elsevierStyleSectionTitle">Introducción</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">La clozapina es un fármaco de probada efectividad, sin embargo, su uso se asoció a la aparición de agranulocitosis y así, fue restringido para esquizofrenia resistente y con un estricto control hematológico. El objetivo de nuestro trabajo es evaluar el riesgo de discrasias sanguíneas en una población de pacientes en tratamiento con clozapina seguidos durante 5 años.</p> <span class="elsevierStyleSectionTitle">Material y métodos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Se trata de una cohorte de pacientes en tratamiento con clozapina en los que se evaluó el riesgo de aparición de alteraciones en la serie blanca, a través de analíticas semanales durante las primeras 18 semanas y mensuales a partir de entonces.</p> <span class="elsevierStyleSectionTitle">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Se trata de una muestra de 271 pacientes, con un media de edad de 32, 3 años y un 63,5% de hombres. La dosis media administrada fue de 227,6<span class="elsevierStyleHsp" style=""></span>mg/día (25 a 600<span class="elsevierStyleHsp" style=""></span>mg). Durante las primeras 18 semanas de seguimiento, se observó una incidencia de neutropenia de 3,0% y de leucopenia de 1,3%. Durante los dos años siguientes, se encontró un nuevo caso de leucopenia y uno de neutropenia (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>120). No se observaron nuevos casos en los pacientes que completaron 5 años de seguimiento (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>69). A lo largo de todo el seguimiento, no hubo ningún caso de agranulocitosis.</p> <span class="elsevierStyleSectionTitle">Conclusión</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Se observó una incidencia de neutropenia del 3%, concentrado en los primeros meses de seguimiento. Ningún paciente presentó agranulocitosis. La evidencia actual disponible sobre efectividad y seguridad de la clozapina y los resultados del presente estudio, hacen adecuado plantearse revisar los protocolos de seguimiento y utilización de este fármaco.</p>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara">Please cite this article as: Pons A, et al. Clozapina y agranulocitosis en España: ¿tenemos una población más segura? Seguimiento hematológico a 5 años de una cohorte de pacientes tratados con clozapina. Rev Psiquiatr Salud Ment (Barc.). 2012;5(1):37–42.</p>" ] ] "multimedia" => array:4 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1378 "Ancho" => 2087 "Tamanyo" => 129764 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">White blood cell count during first 18 weeks (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>231).</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2938 "Ancho" => 2523 "Tamanyo" => 289060 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">18-week count (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>231).</p>" ] ] 2 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Variable \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Initial cohort (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>271) \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Age: mean</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">32.3 (18.2–78.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Men</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">172 (63.5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Women</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">99 (36.5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Mean clozapine dosage (SD)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">227.6 (118.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Diagnosis</span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Schizophrenia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">229 (84.5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Affective psychosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42 (15.5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab203030.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Socio-demographic information and mean clozapine dosage.</p>" ] ] 3 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Week \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">White blood cells</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Neutrophils</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">F</span> value \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Sig. (<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">F</span> value \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Sig. (<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05) \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.0001</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.00001</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.0007</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.0001</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.07 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.005</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.05</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.02</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.01</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.0002</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.05</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.02</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.0003</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.04</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.007</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.0001</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.03</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.0002</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.03</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">18 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.00002</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.008</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab203029.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Repeated measures analysis of variance. Within-subject contrasts were also performed <span class="elsevierStyleItalic">a priori</span> comparing each measure with the initial one. <span class="elsevierStyleItalic">F</span> and <span class="elsevierStyleItalic">P</span> values (in bold, <span class="elsevierStyleItalic"><span class="elsevierStyleBold">P</span></span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold"><</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold">0.05</span>), according to Pillai's Trace, for the white blood cell and neutrophil count during the first 18 weeks of follow-up.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:32 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Schizophrenia Consensus Group of British Association for Psychopharmacology" "etal" => false "autores" => array:1 [ 0 => "T.R. Barnes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/0269881110391123" "Revista" => array:6 [ "tituloSerie" => "J Psychopharmacol" "fecha" => "2011" "volumen" => "25" "paginaInicial" => "567" "paginaFinal" => "620" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21292923" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.M. Mortimer" 1 => "P. Singh" 2 => "C.J. Shepherd" 3 => "J. Puthiryackal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3371/CSRP.4.1.4" "Revista" => array:6 [ "tituloSerie" => "Clin Schizophr Relat Psychoses" "fecha" => "2010" "volumen" => "4" "paginaInicial" => "49" "paginaFinal" => "55" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20643629" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S. Leucht" 1 => "C. Corves" 2 => "D. Arbter" 3 => "R.R. Engel" 4 => "C. Li" 5 => "J.M. Davis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(08)61764-X" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2009" "volumen" => "373" "paginaInicial" => "31" "paginaFinal" => "41" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19058842" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.W. Lewis" 1 => "T.R. Barnes" 2 => "L. Davies" 3 => "R.M. Murray" 4 => "G. Dunn" 5 => "K.P. Hayhurst" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/schbul/sbj067" "Revista" => array:6 [ "tituloSerie" => "Schizophr Bull" "fecha" => "2006" "volumen" => "32" "paginaInicial" => "715" "paginaFinal" => "723" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16540702" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.P. McEvoy" 1 => "J.A. Lieberman" 2 => "T.S. Stroup" 3 => "S.M. Davis" 4 => "H.Y. Meltzer" 5 => "R.A. Rosenheck" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1176/appi.ajp.163.4.600" "Revista" => array:6 [ "tituloSerie" => "Am J Psychiatry" "fecha" => "2006" "volumen" => "163" "paginaInicial" => "600" "paginaFinal" => "610" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16585434" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A meta-analysis of the efficacy of second-generation antipsychotics" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J.M. Davis" 1 => "N. Chen" 2 => "I.D. Glick" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archpsyc.60.6.553" "Revista" => array:6 [ "tituloSerie" => "Arch Gen Psychiatry" "fecha" => "2003" "volumen" => "60" "paginaInicial" => "553" "paginaFinal" => "564" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12796218" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J. Kane" 1 => "G. Honigfeld" 2 => "J. Singer" 3 => "H. Meltzer" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Gen Psychiatry" "fecha" => "1988" "volumen" => "45" "paginaInicial" => "789" "paginaFinal" => "796" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3046553" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A historical perspective of clozapine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "H. Hippius" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Clin Psychiatry" "fecha" => "1999" "volumen" => "60" "numero" => "Suppl. 12" "paginaInicial" => "S22" "paginaFinal" => "S23" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Über in 5-Stellung basisch substituierte 5H-Dibenzo[b,e]-1,4-diazepine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "F. Hunziker" 1 => "F. Künzle" 2 => "J. Schmutz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Helv Chim Acta" "fecha" => "1963" "volumen" => "43" "paginaInicial" => "2337" "paginaFinal" => "2346" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clozapine and agranulocytosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J. Idänpään-Heikkilä" 1 => "E. Alhava" 2 => "M. Olkinuora" 3 => "I. Palva" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Lancet" "fecha" => "1975" "volumen" => "2" "paginaInicial" => "611" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2900986" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clozapine-induced agranulocytosis: a situation report up to August 1976" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B. Anderman" 1 => "R.W. Griffith" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur J Clin Pharmacol" "fecha" => "1977" "volumen" => "11" "paginaInicial" => "199" "paginaFinal" => "201" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/852497" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "H.Y. Meltzer" 1 => "B. Bastani" 2 => "K.Y. Kwon" 3 => "L.F. Ramirez" 4 => "S. Burnett" 5 => "J. Sharpe" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Psychopharmacology (Berl)" "fecha" => "1989" "volumen" => "99" "numero" => "Suppl." "paginaInicial" => "S68" "paginaFinal" => "S72" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Neuroleptika" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R. Grohmann" 1 => "E. Rüther" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:5 [ "titulo" => "Unerwünschte Wirkungen von Psychopharmaka. Ergebnisse der AMÜP-Studie" "paginaInicial" => "42" "paginaFinal" => "133" "edicion" => "1st ed." "serieFecha" => "1994" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Munro" 1 => "D. O'Sullivan" 2 => "C. Andrews" 3 => "A. Arana" 4 => "A. Mortimer" 5 => "R. Kerwin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Psychiatry" "fecha" => "1999" "volumen" => "175" "paginaInicial" => "576" "paginaFinal" => "580" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10789357" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "K. Atkin" 1 => "F. Kendall" 2 => "D. Gould" 3 => "H. Freeman" 4 => "J. Liberman" 5 => "D. O'Sullivan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Psychiatry" "fecha" => "1996" "volumen" => "169" "paginaInicial" => "483" "paginaFinal" => "488" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8894200" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clozapine-induced agranulocytosis. Incidence and risk factors in the United States" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J.M. Alvir" 1 => "J.A. Lieberman" 2 => "A.Z. Safferman" 3 => "J.L. Schwimmer" 4 => "J.A. Schaaf" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199307153290303" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1993" "volumen" => "329" "paginaInicial" => "162" "paginaFinal" => "167" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8515788" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "51Cr release assay of clozapine-induced cytotoxicity: evidence for immunogenic mechanism" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A.V. Pisciotta" 1 => "S.A. Konings" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Clin Psychiatry" "fecha" => "1994" "volumen" => "55" "numero" => "Suppl. B" "paginaInicial" => "S143" "paginaFinal" => "S148" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.C. Athanasiou" 1 => "M. Dettling" 2 => "I. Cascorbi" 3 => "I. Mosyagin" 4 => "B.A. Salisbury" 5 => "K.A. Pierz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4088/JCP.09m05527yel" "Revista" => array:6 [ "tituloSerie" => "J Clin Psychiatry" "fecha" => "2011" "volumen" => "72" "paginaInicial" => "458" "paginaFinal" => "463" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20868635" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Haematological toxicity of clozapine and some other drugs used in psychiatry" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "P.M. Nooijen" 1 => "F. Carvalho" 2 => "R.J. Flanagan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hup.1181" "Revista" => array:6 [ "tituloSerie" => "Hum Psychopharmacol" "fecha" => "2011" "volumen" => "26" "paginaInicial" => "112" "paginaFinal" => "119" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21416507" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Jaquenoud Sirot" 1 => "B. Knezevic" 2 => "G.P. Morena" 3 => "S. Harenberg" 4 => "B. Oneda" 5 => "S. Crettol" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/JCP.0b013e3181acc372" "Revista" => array:6 [ "tituloSerie" => "J Clin Psychopharmacol" "fecha" => "2009" "volumen" => "29" "paginaInicial" => "319" "paginaFinal" => "326" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19593168" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Fehsel" 1 => "S. Loeffler" 2 => "K. Krieger" 3 => "U. Henning" 4 => "M. Agelink" 5 => "V. Kolb-Bachofen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Clin Psychopharmacol" "fecha" => "2005" "volumen" => "25" "paginaInicial" => "419" "paginaFinal" => "426" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16160616" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Dirección General de Farmacia y Productos Sanitarios. Circular n° 10/93 sobre reglamentación específica para la prescripción, dispensación y utilización de leponex. Madrid: Ministerio de Sanidad y Consumo; 1993. Available from: <a class="elsevierStyleInterRef" href="http://www.ub.edu/legmh/disposici/cir1093.htm">http://www.ub.edu/legmh/disposici/cir1093.htm</a>." ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The European experience with use of clozapine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D. Naber" 1 => "H. Hippius" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Hosp Commun Psychiatry" "fecha" => "1990" "volumen" => "41" "paginaInicial" => "886" "paginaFinal" => "890" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clozapine: dangerous orphan or neglected friend?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Farooq" 1 => "M. Taylor" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1192/bjp.bp.110.088690" "Revista" => array:6 [ "tituloSerie" => "Br J Psychiatry" "fecha" => "2011" "volumen" => "198" "paginaInicial" => "247" "paginaFinal" => "249" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21972272" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clozapine: more side effects but still the best antipsychotic" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "X. Kang" 1 => "G.M. Simpson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4088/JCP.09com05497yel" "Revista" => array:6 [ "tituloSerie" => "J Clin Psychiatry" "fecha" => "2010" "volumen" => "71" "paginaInicial" => "982" "paginaFinal" => "983" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20797378" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Italian Collaborative Study Group on the Outcome of Severe Mental Disorders" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "G. Tognoni" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur J Clin Pharmacol" "fecha" => "1999" "volumen" => "55" "paginaInicial" => "685" "paginaFinal" => "690" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10638400" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Tiihonen" 1 => "J. Lönnqvist" 2 => "K. Wahlbeck" 3 => "T. Klaukka" 4 => "L. Niskanen" 5 => "A. Tanskanen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(09)60742-X" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2009" "volumen" => "374" "paginaInicial" => "620" "paginaFinal" => "627" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19595447" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.Y. Meltzer" 1 => "L. Alphs" 2 => "A.I. Green" 3 => "A.C. Altamura" 4 => "R. Anand" 5 => "A. Bertoldi" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Gen Psychiatry" "fecha" => "2003" "volumen" => "60" "paginaInicial" => "82" "paginaFinal" => "91" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12511175" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Restarting clozapine after neutropenia: evaluating the possibilities and practicalities" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E. Whiskey" 1 => "D. Taylor" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "CNS Drugs" "fecha" => "2007" "volumen" => "21" "paginaInicial" => "25" "paginaFinal" => "35" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17696590" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recomendaciones para el cambio de antipsicóticos. Posicionamiento de la Sociedad Española de Psiquiatría y Sociedad Española de Psiquiatría Biológica" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Bernardo" 1 => "E. Vieta" 2 => "J. Saiz Ruiz" 3 => "F. Rico-Villademoros" 4 => "C. Álamo" 5 => "J. Bobes" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Psiquiatr Salud Ment" "fecha" => "2011" "volumen" => "04" "paginaInicial" => "150" "paginaFinal" => "168" ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Continuing clozapine treatment despite neutropenia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D. Esposito" 1 => "F. Rouillon" 2 => "F. Limosin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00228-004-0835-z" "Revista" => array:6 [ "tituloSerie" => "Eur J Clin Pharmacol" "fecha" => "2005" "volumen" => "60" "paginaInicial" => "759" "paginaFinal" => "764" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15660271" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rechallenge in clozapine-induced agranulocytosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.Z. Safferman" 1 => "J.A. Lieberman" 2 => "J.M.J. Alvir" 3 => "A. Howard" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "1992" "volumen" => "339" "paginaInicial" => "1296" "paginaFinal" => "1297" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1349691" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:3 [ "identificador" => "xack37114" "titulo" => "Acknowledgements" "texto" => "<p id="par0150" class="elsevierStylePara elsevierViewall">We gratefully acknowledge the support of the <span class="elsevierStyleGrantSponsor" id="gs0005">Government of Cataluña, the Commission for Universities and the Development Office of the Department of Innovation, Universities and Enterprise (DIUE)</span><span class="elsevierStyleGrantNumber" refid="gs0005">2009SGR1295</span> and of the <span class="elsevierStyleGrantSponsor">Carlos III Health Institute, Biomedical Research Centre in the Mental Health Network</span> (<span class="elsevierStyleItalic">CIBERSAM</span> in English; for JU, AP, AB and MB) and with the support of the Josep Font Research Grant from the <span class="elsevierStyleGrantSponsor">Clinical Hospital of Barcelona</span> (for JU).</p>" ] ] ] "idiomaDefecto" => "en" "url" => "/21735050/0000000500000001/v1_201305031529/S2173505012000210/v1_201305031529/en/main.assets" "Apartado" => array:4 [ "identificador" => "7688" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Originals Articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735050/0000000500000001/v1_201305031529/S2173505012000210/v1_201305031529/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173505012000210?idApp=UINPBA00004N" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 8 | 0 | 8 |
2024 October | 26 | 4 | 30 |
2024 September | 61 | 13 | 74 |
2024 August | 51 | 13 | 64 |
2024 July | 48 | 10 | 58 |
2024 June | 42 | 5 | 47 |
2024 May | 29 | 14 | 43 |
2024 April | 37 | 2 | 39 |
2024 March | 50 | 10 | 60 |
2024 February | 64 | 6 | 70 |
2024 January | 47 | 3 | 50 |
2023 December | 52 | 3 | 55 |
2023 November | 31 | 5 | 36 |
2023 October | 53 | 3 | 56 |
2023 September | 30 | 0 | 30 |
2023 August | 15 | 2 | 17 |
2023 July | 22 | 4 | 26 |
2023 June | 16 | 4 | 20 |
2023 May | 28 | 1 | 29 |
2023 April | 21 | 1 | 22 |
2023 March | 14 | 3 | 17 |
2023 February | 17 | 2 | 19 |
2023 January | 21 | 3 | 24 |
2022 December | 30 | 9 | 39 |
2022 November | 29 | 9 | 38 |
2022 October | 21 | 6 | 27 |
2022 September | 22 | 12 | 34 |
2022 August | 27 | 9 | 36 |
2022 July | 24 | 7 | 31 |
2022 June | 18 | 6 | 24 |
2022 May | 30 | 19 | 49 |
2022 April | 35 | 14 | 49 |
2022 March | 30 | 15 | 45 |
2022 February | 28 | 9 | 37 |
2022 January | 46 | 7 | 53 |
2021 December | 44 | 12 | 56 |
2021 November | 30 | 11 | 41 |
2021 October | 28 | 9 | 37 |
2021 September | 34 | 13 | 47 |
2021 August | 28 | 18 | 46 |
2021 July | 57 | 10 | 67 |
2021 June | 35 | 10 | 45 |
2021 May | 51 | 14 | 65 |
2021 April | 93 | 17 | 110 |
2021 March | 42 | 6 | 48 |
2021 February | 43 | 4 | 47 |
2021 January | 56 | 12 | 68 |
2020 December | 29 | 5 | 34 |
2020 November | 34 | 10 | 44 |
2020 October | 28 | 6 | 34 |
2020 September | 29 | 11 | 40 |
2020 August | 23 | 2 | 25 |
2020 July | 44 | 11 | 55 |
2020 June | 29 | 7 | 36 |
2020 May | 22 | 5 | 27 |
2020 April | 24 | 3 | 27 |
2020 March | 33 | 6 | 39 |
2020 February | 28 | 5 | 33 |
2020 January | 33 | 6 | 39 |
2019 December | 25 | 10 | 35 |
2019 November | 22 | 3 | 25 |
2019 October | 32 | 4 | 36 |
2019 September | 35 | 4 | 39 |
2019 August | 28 | 3 | 31 |
2019 July | 28 | 16 | 44 |
2019 June | 56 | 30 | 86 |
2019 May | 135 | 67 | 202 |
2019 April | 54 | 15 | 69 |
2019 March | 26 | 0 | 26 |
2019 February | 28 | 10 | 38 |
2019 January | 25 | 5 | 30 |
2018 December | 26 | 5 | 31 |
2018 November | 44 | 3 | 47 |
2018 October | 34 | 3 | 37 |
2018 September | 17 | 7 | 24 |
2018 August | 19 | 2 | 21 |
2018 July | 21 | 3 | 24 |
2018 June | 10 | 5 | 15 |
2018 May | 38 | 5 | 43 |
2018 April | 53 | 8 | 61 |
2018 March | 11 | 4 | 15 |
2018 February | 11 | 2 | 13 |
2018 January | 11 | 8 | 19 |
2017 December | 14 | 0 | 14 |
2017 November | 7 | 2 | 9 |
2017 October | 17 | 4 | 21 |
2017 September | 10 | 2 | 12 |
2017 August | 12 | 4 | 16 |
2017 July | 17 | 6 | 23 |
2017 June | 25 | 1 | 26 |
2017 May | 28 | 1 | 29 |
2017 April | 26 | 2 | 28 |
2017 March | 18 | 57 | 75 |
2017 February | 13 | 1 | 14 |
2017 January | 15 | 3 | 18 |
2016 December | 28 | 8 | 36 |
2016 November | 16 | 4 | 20 |
2016 October | 28 | 3 | 31 |
2016 September | 26 | 3 | 29 |
2016 August | 20 | 6 | 26 |
2016 July | 25 | 2 | 27 |
2016 June | 23 | 8 | 31 |
2016 May | 18 | 6 | 24 |
2016 April | 24 | 9 | 33 |
2016 March | 28 | 7 | 35 |
2016 February | 18 | 10 | 28 |
2016 January | 23 | 7 | 30 |
2015 December | 18 | 6 | 24 |
2015 November | 16 | 3 | 19 |
2015 October | 25 | 4 | 29 |
2015 September | 11 | 5 | 16 |
2015 August | 25 | 7 | 32 |
2015 July | 20 | 8 | 28 |
2015 June | 8 | 0 | 8 |
2015 May | 18 | 3 | 21 |
2015 April | 21 | 6 | 27 |
2015 March | 35 | 15 | 50 |
2015 February | 28 | 7 | 35 |
2015 January | 31 | 3 | 34 |
2014 December | 34 | 9 | 43 |
2014 November | 20 | 2 | 22 |
2014 October | 30 | 7 | 37 |
2014 September | 39 | 2 | 41 |
2014 August | 25 | 1 | 26 |
2014 July | 20 | 3 | 23 |
2014 June | 25 | 3 | 28 |
2014 May | 26 | 4 | 30 |
2014 April | 6 | 2 | 8 |
2014 March | 15 | 3 | 18 |
2014 February | 13 | 1 | 14 |
2014 January | 12 | 0 | 12 |
2013 December | 17 | 5 | 22 |
2013 November | 22 | 10 | 32 |
2013 October | 38 | 8 | 46 |
2013 September | 24 | 4 | 28 |
2013 August | 28 | 8 | 36 |
2013 July | 17 | 3 | 20 |